Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan.
Quote | Aytu BioPharma Inc. (NASDAQ:AYTU)
Last: | $2.70 |
---|---|
Change Percent: | -2.22% |
Open: | $2.76 |
Close: | $2.70 |
High: | $2.7898 |
Low: | $2.67 |
Volume: | 14,306 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | Aytu BioPharma Inc. (NASDAQ:AYTU)
2024-06-18 09:00:17 ET More on Aytu BioScience Aytu BioPharma, Inc. (AYTU) Q3 2024 Earnings Call Transcript Aytu BioPharma up 5% as quarterly results beat on both lines Seeking Alpha’s Quant Rating on Aytu BioScience Historical earnings data for Aytu B...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Message Board Posts | Aytu BioPharma Inc. (NASDAQ:AYTU)
Subject | By | Source | When |
---|---|---|---|
AYTU BIOPHARMA: LEADING THE ADHD DRUG MARKET$AYTUExcited to share an article about Aytu BioPharma, I | 11/28/2023 7:55:36 AM | ||
But Josh got paid! Reverse split and huge | Drugdoctor | investorshub | 02/22/2023 1:52:42 PM |
whytestocks: $AYTU News Article - Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Resu | whytestocks | investorshangout | 02/21/2023 8:30:47 PM |
whytestocks: $AYTU News Article - Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT(R) Prescrip | whytestocks | investorshangout | 11/30/2022 4:00:55 PM |
whytestocks: $AYTU News Article - Aytu BioPharma Ranked Among Fastest-Growing Companies in North Ame | whytestocks | investorshangout | 11/17/2022 5:00:50 PM |
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...